← All trials
NCT06076213
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2023
- Primary completion
- Dec 1, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 10, 2023
- Last posted
- Dec 12, 2023
- Enrollment
- 1408
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of the Democratic Republic of the CongoLead sponsor
- Global Health Innovative Technology FundCollaborator
- Government of the Democratic Republic of the CongoReponsible party - principal investigator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.